Cervical and vaginal secretions play a protective role in preventing sexually transmitted infections (STI) Defining this activity and identifying the antimicrobial components is crucial as these factors could be exploited in the development of topical microbicides and because vaginal application of drugs should not interfere with critical host defenses. This proposal focuses on the mucosal factors that protect against genital herpes, one of the most prevalent STI and a major co-factor for HIV. Cervicovaginal secretions obtained from healthy women substantially reduce HSV infection and protect mice from vaginal challenge. Preliminary studies suggest that antimicrobial peptides play a key role in this innate protection. The relative contribution and mechanism of anti-HSV activity for human neutrophil peptides1-4, epithelial defensins HD-5 and HD-6, and secretory leukocyte protease inhibitor (SLPI) will be elucidated. HSV must overcome the cervical secretion defenses to establish infection and may have developed strategies to escape these host factors, perhaps through transcriptional regulation. Consistent with this notion, exposure of human cervical epithelial cells to HSV leads to a reduction in SLPI. In addition to serving as an escape mechanism, the changes in the mucosal environment triggered by HSV may enhance susceptibiity to HIV or HIV replication. In additoin to the reduction in SLPI, HSV induces a rapid increase in pro-inflammatory cytokines and chemokines and culture supernatants obtained from HSV-exposed cellss promote activation of latent HIV, mediated in part by IL-6 and TNF-Dlpha. These studies provide a molecular basis for the epidemiological findings of enhanced HIV acquisition in the setting of HSV infection. Building on these observations, the proposed studies will evaluate the interplay between HSV and genital tract mucosal defenses focusing on defensins and SLPI. The paradigm being tested is that genital tract secretions protect against HSV but the virus has developed countermeasures to evade this defense by modulating host protective factors. Moreover, the virus-induced changes may alter the genital tract environment to promote HIV co-infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI065309-02
Application #
7074622
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Turpin, Jim A
Project Start
2005-06-15
Project End
2010-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
2
Fiscal Year
2006
Total Cost
$402,411
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Buckley, Niall; Huber, Ashley; Lo, Yungtai et al. (2016) Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women. Am J Reprod Immunol 75:146-54
Nakra, Natasha A; Madan, Rebecca Pellett; Buckley, Niall et al. (2016) Loss of Innate Host Defense Following Unprotected Vaginal Sex. J Infect Dis 213:840-7
Petro, Christopher D; Weinrick, Brian; Khajoueinejad, Nazanin et al. (2016) HSV-2 ?gD elicits Fc?R-effector antibodies that protect against clinical isolates. JCI Insight 1:
Seay, Kieran; Khajoueinejad, Nazanin; Zheng, Jian Hua et al. (2015) The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. J Virol 89:9559-70
Murphy, Kerry; Richardson, Barbra A; Dezzutti, Charlene S et al. (2015) Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women. Am J Reprod Immunol 74:313-22
Costantini, Lindsey M; Irvin, Susan C; Kennedy, Steven C et al. (2015) Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays. Virology 476:240-8
Irvin, Susan C; Herold, Betsy C (2015) Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk. PLoS One 10:e0121135
Nixon, Briana; Jandl, Thomas; Teller, Ryan S et al. (2014) Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother 58:1153-60
Herold, Betsy C; Dezzutti, Charlene S; Richardson, Barbra A et al. (2014) Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr 66:65-73
Murphy, Kerry; Irvin, Susan C; Herold, Betsy C (2014) Research gaps in defining the biological link between HIV risk and hormonal contraception. Am J Reprod Immunol 72:228-35

Showing the most recent 10 out of 44 publications